AERAMI THERAPEUTICS
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft mist device that allows convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution. It was founded in 2010 and headquartered in Durham, North Carolina.
AERAMI THERAPEUTICS
Industry:
Biotechnology Diabetes Health Care Medical Therapeutics
Founded:
2010-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.aerami.com
Total Employee:
11+
Status:
Active
Total Funding:
133.54 M USD
Technology used in webpage:
SPF Google Maps Amazon Microsoft Exchange Online Office 365 Mail Google Maps API Microsoft Azure DNS GoDaddy DNS AWS Global Accelerator Google Maps For Work
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Espervita Therapeutics
Espervita Therapeutics is a developer of metabolic reprogramming therapies used for the treatment of cancers.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Sunstone Therapies
Sunstone Therapies focuses on the research and commercial delivery of psychedelic therapies for cancer patients.
Current Advisors List
Board_member
2020-11-01
Current Employees Featured
Darlene Deptula-Hicks Board Member & Audit Committee Chair @ Aerami Therapeutics
Board Member & Audit Committee Chair
2021-10-01
Barry Deutsch CFO @ Aerami Therapeutics
CFO
2021-11-15
Lisa Yañez Chief Operating Officer @ Aerami Therapeutics
Chief Operating Officer
2022-06-01
Lisa Yañez Incoming Chief Executive Officer @ Aerami Therapeutics
Incoming Chief Executive Officer
Founder
Investors List
SternAegis
SternAegis investment in Venture Round - Aerami Therapeutics
Molex Ventures
Molex Ventures investment in Private Equity Round - Aerami Therapeutics
Molex Ventures
Molex Ventures investment in Corporate Round - Aerami Therapeutics
SternAegis
SternAegis investment in Venture Round - Aerami Therapeutics
SternAegis
SternAegis investment in Venture Round - Aerami Therapeutics
John Patton
John Patton investment in Venture Round - Aerami Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-21 | Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer |
| 2022-06-16 | Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer |
| 2021-11-18 | Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer |
Official Site Inspections
http://www.aerami.com Semrush global rank: 7.09 M Semrush visits lastest month: 890
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Aerami Therapeutics"
Board of Directors :: Aerami Therapeutics Holdings, Inc.
Mr. Welch has served on the Aerami Board since January 2020. He served as Chief Technology Officer of Phillips-Medisize, a Molex Company, until his retirement in December 2021. Phillips …See details»
Management Team :: Aerami Therapeutics Holdings, Inc.
Darlene Deptula-Hicks has served on the board of directors and as audit committee chair of Aerami since October 2021 and formally accepted Aerami’s Chief Financial Officer role in …See details»
Aerami Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Prior to Aerami, Josh held senior executive roles in the contract research organization (CRO) sector at Syneos Health and within the WPP agency network. “We are pleased to welcome …See details»
Aerami Therapeutics - Crunchbase Company Profile
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft …See details»
Aerami Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Aerami Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Aerami Therapeutics Holdings, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Aerami Therapeutics Holdings, Inc. of Durham, NC. Get the latest business insights from Dun & …See details»
Aerami Therapeutics shuts down without explanation
Aug 30, 2024 Aerami at one time attempted to reach the public markets through a SPAC transaction that was ... Whitaker in July joined the board of directors of the global clinical research organization Icon ...See details»
Aerami Therapeutics Company Profile - Office Locations ... - Craft
Aerami Therapeutics (formerly known as Dance Biopharm) is a company focused on developing inhaled formulations of medicines to treat diabetes and other serious chronic diseases. The …See details»
Press Release Distribution and Management - GlobeNewswire
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of …See details»
Aerami Therapeutics - Overview, News & Similar companies
May 31, 2023 DURHAM, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the …See details»
Aerami Therapeutics Company Profile 2024: Valuation, Funding ...
Aerami Therapeutics General Information Description. Developer of therapies intended for the treatment of severe respiratory and chronic diseases. The company offers inhaled therapies …See details»
Aerami Therapeutics to Host Virtual Investor Day with Leading …
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of …See details»
Innovative Inhaled Drug Delivery Developer Aerami Therapeutics …
Dec 7, 2021 AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib, targeted to advance in 2022 into a Phase 2/3 clinical trial for PAH Aerami expected to file for 510(k) …See details»
Company Information :: Aerami Therapeutics Holdings, Inc.
Company Contact Aerami Therapeutics Holdings, Inc. 600 Park Offices Drive 300 Durham, NC 27709 info@aerami.comSee details»
Aerami - Company Profile - Tracxn
Nov 5, 2024 Aerami ranks 6th among 80 active competitors. 20 of its competitors are funded while 11 have exited. Overall, Aerami and its competitors have raised over $624M in funding …See details»
Aerami - Raised $57.8M Funding from 4 investors - Tracxn
2 days ago Aerami has raised a total funding of $57.8M over 5 rounds from 4 investors. Investors include SRG, SternAegis Ventures and 2 others. Their latest funding round was of …See details»
Aerami Therapeutics to Present Pharmacokinetic Data Supporting …
May 11, 2023 Aerami will also be featured as a presenting company at the ATS Respiratory Innovation Summit (RIS) being held at the Marriott Marquis Washington from May 19-20, …See details»
Aerami Therapeutics Appoints Joshua Ziel as COO and Interim …
Exploratory endpoints such as 6MWD, changes in World Health Organization Functional Class and Borg Dyspnea Score will provide additional information in preparation for future Phase 3 …See details»
ESAA announces new Executive Director: Erin Ciezki
3 days ago The Environmental Services Association of Alberta (ESAA) has announced Erin Ciezki as the new Executive Director.Ciezki joined ESAA in July of 2023 as the Manager of …See details»
Board of Directors :: Aerami Therapeutics Holdings, Inc.
Mr. Welch has served on the Aerami Board since January 2020. He served as Chief Technology Officer of Phillips-Medisize, a Molex Company, until his retirement in December 2021. Phillips …See details»